




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C08B 37/16, A61K 47/40</b>		A1	(11) International Publication Number: <b>WO 99/45032</b>
			(43) International Publication Date: 10 September 1999 (10.09.99)
(21) International Application Number: <b>PCT/FI99/00167</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>4 March 1999 (04.03.99)</b>			
(30) Priority Data: 980489                      4 March 1998 (04.03.98)                      FI			
(71)(72) Applicants and Inventors: <b>KHOMUTOV, Alexei Radievich [RU/RU]; Apartment 447, Lyusinovskaya Street, 68, Moscow, 113162 (RU). YAKOVLEV, Dmitry Yurievich [RU/US]; Apartment 833, Profsoyusnaya Street, 114-6, Moscow, 117437 (RU). KHOMUTOV, Radii Mikhailovich [RU/RU]; Apartment 46, Profsoyusnaya Street, 43-1, Moscow, 117420 (RU). KORPELA, Timo [FI/FI]; Kasarminkatu 5 as 8, FIN-20500 Turku (FI).</b>			
(74) Common Representative: <b>KORPELA, Timo, Kalevi; Kasarminkatu 5 as 8, FIN-20500 Turku (FI).</b>		Published With international search report.	

(54) Title: NOVEL DERIVATIVES OF CYCLODEXTRINS

## (57) Abstract

The present invention is directed to novel aminoxy-cyclodextrin derivatives of the formula (1):  $CD - (X - Y - ONH_2)_n$ , wherein CD is a mono- or polydeoxy  $\alpha$ -,  $\beta$ -, or  $\gamma$ -cyclodextrin, carrying in its 6-, 3- and/or 2-position a group containing the aminoxy group, and optionally carrying substituents different from  $(X - Y - ONH_2)$ , Y is a linker group between the aminoxy group and the mono- or polydeoxy-CD group, X is a functional group or an atom necessary to connect the linker Y and the deoxy CD group, or Y is a direct bond when X is a direct bond, and n is  $\geq 1$ , but  $\leq 24$ , 21 and 18 for  $\alpha$ -,  $\beta$ - or  $\gamma$ -cyclodextrin, respectively, the protected aminoxy derivatives thereof, as well the methods for their preparation and use.



*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## NOVEL DERIVATIVES OF CYCLODEXTRINS

## FIELD OF THE INVENTION

5


This invention relates to the design and synthesis of earlier unknown chemical derivatives of cyclodextrins. The novel compounds exert a number of useful properties which make them applicable as complexants, solubilizers, carbonyl reagents, catalysts, or starting materials for the synthesis of products to be employed in pharmaceuticals, cosmetics, agriculture or in scientific laboratories.

## BACKGROUND OF THE INVENTION

15

$\alpha$ -,  $\beta$ - and  $\gamma$ -Cyclodextrins ( $\alpha$ -CD,  $\beta$ -CD and  $\gamma$ -CD) are cyclic oligosaccharides consisting of 6, 7 or 8 glucopyranose units, respectively, which are joined together by  $\alpha(1-4)$  linkages:

20

m=6  $\alpha$ -CDm=7  $\beta$ -CDm=8  $\gamma$ -CD

25

Cyclodextrins (termed hosts) can imbibe certain molecules or parts thereof (termed guests) into their center cavities. The noncovalent reversible adducts or inclusion complexes formed between the host and the guest can drastically change the properties of the parent guest molecules in diverse ways, such as to increase solubility, decrease volatility, protect from chemical or light-catalyzed reactions, change the location of absorption of complexed drugs in the intestine, etc.

35

Parent CDs can be covalently modified with a number of reagents to form chemical derivatives. The derivatives can

normally bind similar guest compounds as do the parent CDs, but the properties of the complexes can be changed. A description on the syntheses of CD derivatives and the properties of inclusion complexes of both parent and  
5 modified cyclodextrins can be found for instance in Croft, A.P. & Bartsch, R.A. "Synthesis of Chemically Modified Cyclodextrins", Tetrahedron, 1983, V. 39, No 9, P. 1417-14-71 Szejtli, J. "Cyclodextrin Technology", Kluwer Academic Publishers, Dordrecht, 1988, pp. 1-450.

10

Some derivatives of  $\beta$ -CD have a higher solubility than do the parent compound and hence they are often preferable complexants and solubilizers. The potential of the chemical derivatives of  $\beta$ -CD is amplified by its low price as a  
15 starting material in comparison to  $\alpha$ - and  $\gamma$ -CDs. In contrast to  $\beta$ -CD, the more expensive  $\alpha$ - and  $\gamma$ -CDs are readily water soluble and can be used without chemical derivatization for certain purposes. This is illustrated by a number of reports on their complexes with various guest  
20 compounds such as steroid hormones, cholesterol or its derivatives and with some drugs. Appropriately alkylated or hydroxyalkylated  $\gamma$ -CDs are also good complexants since their inclusion complexes do not precipitate even at high concentration, as stated in EP 06792.

25

A large number of papers deals with the syntheses of CD chemical derivatives and their application for divergent purposes (see e.g. Szejtli, J. "Cyclodextrin Technology" 1988) clearly showing the importance of the CD derivatives.

30

#### SUMMARY OF THE INVENTION

The present invention describes novel CD derivatives carrying specific functions containing an aminoxy ( $H_2NO-$ )  
35 group covalently connected to a glucopyranose unit of CD. These derivatives have significantly different properties from the CD derivatives known in the prior art and thus


they enlarge the area of application of CDs. The present invention also describes the preparation and use of the said novel CD derivatives as such or complexed with guest molecules or further chemically modified.

5

## DETAILED DESCRIPTION OF THE INVENTION

The present invention is related to an earlier unknown type of  $\alpha$ -,  $\beta$ - or  $\gamma$ -CD chemical derivatives containing the aminooxy ( $\text{H}_2\text{NO}$ -) functional group attached to the CD core and having the general formula 1:

10



formula 1

wherein CD is mono- or polydeoxy  $\alpha$ -,  $\beta$ - or  $\gamma$ -CD, carrying in its 6-, 3- and/or 2-position the aminooxy function containing group, and wherein Y is a linker arm connected to deoxy-CD by means of X, which is a direct bond, or a functional group or an atom necessary to connect the linker Y and the deoxy-CD, whereby Y is a direct bond when X is a direct bond. The integer n is equal to or larger than one and cannot be more than 18, 21 and 24 for  $\alpha$ -,  $\beta$ - and  $\gamma$ -CD, respectively.

20

The invention also relates to the compounds of the formula 1, wherein the aminooxy group is in protected form, especially in the form of the 1-ethoxy-ethylideneaminooxy group,  $-\text{O}-\text{N}=\text{C}(\text{CH}_3)\text{OC}_2\text{H}_5$ , or as the acetone oxime group,  $-\text{O}-\text{N}=\text{C}(\text{CH}_3)_2$ .

30

The aminooxy-CDs of formula 1 preferably carry one or several  $\text{H}_2\text{NO}$ -groups attached to 6-hydroxy groups (see examples I-IV). By utilizing the different reactivities of primary and secondary hydroxyl groups (primary hydroxyls more reactive than secondary), and if necessary, suitably protected hydroxyl groups, one can discriminate between the reaction at the "top" (primary) hydroxyls and at the

35

"bottom" (secondary) hydroxyls of the CD molecules (see Croft et. al. supra). These latter types may be important for synthesizing artificial receptors, carriers and catalysts based on the CD-core.

5

In the compound of the formula 1, CD is a mono- or polydeoxy  $\alpha$ -,  $\beta$ - or  $\gamma$ -cyclodextrin. In these compounds, one or more hydroxy groups in the positions 6, 3 and/or 2 of CD are replaced with a (X-Y-ONH<sub>2</sub>) fragment, and specifically, together with primary hydroxy groups, one or more secondary hydroxy group can also be substituted with a (X-Y-ONH<sub>2</sub>) fragment. The compound according to the invention carrying aminoxy groups can optionally carry further substituents. In the aminoxy-CD, one or more hydroxy groups in the 6-, 3- and/or 2-position may be also substituted e.g. into H<sub>2</sub>N-, HS-, -COOH, alkoxy, such as C<sub>1</sub>-C<sub>6</sub>-alkoxy, aryloxy, aryl being preferably phenyl, benzyl or tolyl, or acyloxy groups, acyl being preferably derived from C<sub>1</sub>-C<sub>6</sub>-carboxylic or benzoic acid. Alkyl-, aryl- and acyloxy may carry additional functional groups in a side chain or aromatic ring.

Y is a "linker arm, or linking group" and serves as a bridge between the aminoxy (H<sub>2</sub>NO-) group and the deoxy-CD moiety. Usually Y is alkylene, alkenylene with one or more double bonds which may be either isolated or conjugated, alkynylene with one or more triple bonds which may be either isolated or conjugated, or arylene or arylalkylene fragments where aryl may be substituted or not substituted, such as phenylene. The alkylene, alkenylene and alkynylene fragments may be linear or branched and preferably contain 2-12 C-atoms in the chain. One or more of the chain members (methylene groups) may be replaced by -NH-, -O-, -S-, -S-S-, -C(O)NH-, -C(O)O-, -OP(O)(OH)O-, -S(O)-, SO<sub>2</sub>-, -CHR-, where R is preferably alkyl, aryl, -OR', -NH<sub>2</sub>, -NHR', -NR'<sub>2</sub>, -OH, -COOH, or -ONH<sub>2</sub> groups and where

R' is alkyl, aryl, or acyl. As R and R', aryl is preferably phenyl, aryl lower alkyl, such as benzyl or tolyl.

X is preferably -O-, -S-, -NH-, -NR"-, -OCO-, -NH-O-, =NO-,  
5 -NHC(O)-, -OP(O)(OH), -R"C=NO-, where R" is alkyl.

R, R' and R" when having the meaning of alkyl, are preferably linear or branched C<sub>1</sub> - C<sub>6</sub>-alkyl, in the meaning of acyl they are preferably derived from linear or branched  
10 C<sub>1</sub>-C<sub>6</sub>-carboxylic acids or benzoic acid.

In the preferred compounds of formula 1, Y is alkylene or alkenylene of 2-12, preferably 2-6 C-atoms, wherein one or more of the chain members may be replaced by -NH-, =N-O-, -  
15 O-, -S-, -C(O)NH-, -C(O)O-, or -CHR<sub>1</sub>- wherein R<sub>1</sub> is methyl, ethyl or propyl and X is -O-, -S-, -NH-, -OC(O)- or -NH-O-.

The compounds of the formula 1 are weak bases (usually the pK of the H<sub>2</sub>NO-group is between 4.0 - 6.0) and their  
20 solubility is different from the parent CD molecules. As indicated by the pK values, a unique possibility exists to regulate the ionic form of the compounds of formula 1 by solvent acidity near the physiological pH-region. That means that a low pH favours complexation of ionic guest  
25 molecules, while high pH-values favour the contribution of non-ionic interactions between host and guest. With related compounds containing alkylamino functions, protonation-deprotonation takes place only at around pH 10 (Boger, J. et al. *Helv.Chim.Acta*, 1978, V. 61, P. 2190-2218).

30

The compounds of formula 1 are carbonyl reagents like other O-substituted hydroxylamines. They react rapidly and quantitatively with various aldehydes and ketones forming oximes which have high stability in water solution at a  
35 broad range of pHs. These properties of aminooxy-CDs enable the synthesis of a multitude of CD derivatives in addition to those of the formula 1; for example, immobilization of

CDs on solid supports and subsequent use in the chromatography of various important compounds such as stereoisomers of pharmaceuticals. In addition, oligo- and polymeric materials are readily obtained in a single-step by allowing  
5 dialdehydes or diketones to react with di- or polysubstituted aminoxy-CDs in aqueous solution. Such oligo- or polymeric materials are advantageously used as semipermeable or stereoselective membranes, as prolonged-release supports for drugs, sanitary, cosmetics or agricultural  
10 materials. Further, the chemical reactivity properties of the aminoxy functions enable one to stabilize CD-complexes of certain physiologically active, highly reactive, aldehydes and ketones - for instance, steroids, prostaglandins and vitamins - by anchoring these into CDs via the  
15 oxime bond in addition to the stabilization involved in the host-guest interaction. Since the stabilization effect is cumulative (not additive), the protection conferred by molecular complexation can be drastically increased.

20 Inclusion complexes in general may be additionally stabilized by means of oxime formation with a suitable aldehyde or ketone. In this case the inclusion complex is first formed which is then reacted with the aldehyde or ketone to form the inclusion complex oxime. Thus the existence of steric  
25 hindrance at the cavity entrance may prevent complex from dissociation.

While the oxime bond is stable in water solutions, especially at extreme pH values, it may slowly decompose. This  
30 property can be utilized for the slow release of aminoxy-CD bound drugs in the stomach and intestine.

Since aminoxy-CDs are carbonyl reagents, they may inhibit certain crucial enzymes in the metabolism of cells, such as  
35 PLP-, pyruvate-, or ketobutyrate-dependent enzymes. The inhibitory potency will depend on the affinity of the coenzyme to protein.



The existence of aminoxy group(s) bound to a CD molecule means that such compounds, like other O-substituted hydroxylamines, are capable of reacting directly with cytidine and adenosine. This was confirmed by the reaction of aminoxy-CDs of formula 1 with 4-thiouracil, 6-mercapto-  
5 purine riboside or their derivatives and even cytidines themselves (see examples XIII and XIV). Hence, the compounds of formula 1 can be useful for the modification of nucleotides, nucleosides, bases, nucleoside coenzymes and nucleic  
10 acids, such as for the formation of nucleotide and nucleoside pyrimidine and purine derivatives of aminoxy CD, wherein the pyrimidine and purine preferably are cytosine or adenine as such, or in the form of their corresponding  
15 derivatives.

At neutral and slightly acidic pH, the aminoxy groups of compound of formula 1 are not protonated. The nonprotonated aminoxy groups are strong nucleophiles capable of  
20 reacting with an activated carboxyl group (esters, activated esters, mixed anhydrides, anhydrides, etc.) even in water solutions forming stable hydroxamic acids. These can have new useful properties such as the ability to complex certain metal ions. Combined metal ion and CD complexation  
25 functions of the aminoxy-CD derivatives may be used for recovering of metal ions from solutions.

A comparison of the compounds of the present invention with amino group containing CDs (*Boger, J. et al. Helv.Chim.Acta*, 1978, V. 61, P. 2190-2218) demonstrates various  
30 advantages for the aminoxy-CDs. The basic disadvantages of the alkylamino-CDs are the high pKs necessitating alkaline reaction conditions during the derivatization reactions and the low stability of the Schiff-base bond between the amino  
35 and aldehyde or keto groups in aqueous solutions.

The high nucleophilicity of the aminoxy ( $\text{H}_2\text{NO}-$ ) group,

its easy introduction into different sites of the CD molecules with different spacer arms make the aminooxy-CDs and their derivatives promising for the construction of catalytically active CDs.


5

The compounds of formula 1 can be prepared in different ways, and the present invention is also directed to the processes for the preparation of the novel compounds of the formula 1. Such processes are:


10

a) alkylation of a corresponding CD derivative with an aminooxy-protected, reactively substituted aminooxy derivative, for example with a compound of the formula 3':

15




20



wherein  $R_2$ ,  $R_3$  and  $R_4$  are independently hydrogen, or a substituent (see Croft et. al. supra) having no reactive functional group, being typically alkyl, such as  $\text{C}_1$ - $\text{C}_6$ -alkyl, or aryl, such as phenyl, benzyl or tolyl, whereby at least one of the positions 6, 3 and/or 2 contains a hydroxy group, preferably the 6-hydroxy group, W means  $\text{OC}_2\text{H}_5$  or  $\text{CH}_3$ , m and Y are as defined above and Z is a reactive group, such as Cl, Br, I, tosyl or mesyl, and optionally removing the protecting group. In this case a compound of the formula 1 is obtained, wherein X is O. In the above formula, when W is  $\text{OC}_2\text{H}_5$ , the compound (3) is protected in the form of the 1-ethoxy-ethylideneaminooxy derivative, and when W is  $\text{CH}_3$ , in the form of the acetone oxime derivative.


- Suitable compounds (3') are e.g. 4-(ethoxyethylideneamino-oxy)bromobutene-2, ethyl N-(ω-iodoalkyloxy)acetimidate, the sodium salt of 3-(ethoxyethylideneamino-oxy)-2-bromo-bromopropionic acids etc. The compounds (3') are used in alkaline water solutions, using e.g. alkali or alkaline-earth metals, or hydrides, hydroxides, oxides, carbonates, hydrocarbonates thereof; or quaternary ammonium salts, mono-, di- and trialkylamines carrying lower (C<sub>1</sub>-C<sub>4</sub>) linear or branched alkyl groups being the same or different in alkaline water-organic mixtures (the organic solvent being e.g. a lower (1-4C) alcohol, dioxane, tetrahydrofuran, glyme, cellosolve, dimethylsulfoxide, dimethylformamide) or in liquid ammonia at temperatures from elevated (about 100°C or higher) to ambient temperature. The substitution degree depends on the reaction conditions and the products can have either only few primary hydroxyls being substituted or also secondary hydroxy groups may be involved in the reaction.
- b) Alkylating an activated CD-derivative, such as a tosylate, mesylate, halogen derivative, epoxide, activated ester, with an aminoxy-protected, functionally substituted hydroxylamine



- wherein R'<sub>2</sub>, R'<sub>3</sub> and R'<sub>4</sub> are hydroxy, or an activated group such as tosyl, mesyl, halogen, ester, epoxide, and X, Y and W are as defined above, and thereafter optionally removing the protecting group. In this reaction, aminoxy CD derivatives are obtained, wherein X is not only O, but also e.g. sulfur or an imino group.

Suitable compounds of the formula (4) are e.g. ethyl N-( $\omega$ -mercaptoalkyloxy)-acetimidate, ethyl N-( $\omega$ -aminoalkyloxy)acetimidate or ethyl N-hydroxyacetimidate itself.

- 5 The activated CD-derivative can also be e.g. a mono- or poly-N-hydroxysuccinimide activated CD-derivative having a -COOH group, which is reacted with the compound of formula 4, where X is a HN-group.
- 10 According to an embodiment, one or more of the secondary hydroxy groups in the CD derivative may be unsubstituted or substituted with groups other than activating tosyl, mesyl or halogen, such as with those described above.
- 15 c) Modifying a functionally-substituted CD derivative having of the formula (5)



- 25 wherein at least one of the groups  $R''_2$ ,  $R''_3$ , and  $R''_4$  mean thiol-, amino-, karboxy- etc. group possibly linked directly to deoxy-CD-ring, or mean alkyleneoxy- or acyloxy groups, which contain at least one thiol-, amino-, karboxy-, etc. group, or their derivative, and the remaining functional
- 30 groups are hydroxyl groups or they have the meaning described in claim 7 for the substituents, and exist, if necessary, in a protected form, typical example being unsubstituted alkoxy, aryloxy, or acyloxy, modified with an appropriate aminoxy protected substituted hydroxylamine
- 35 according to formula (3'), after which the protecting group(s) are removed, or

d) With modifying such CD-derivative, having one or more keto or aldehyde function at 2-, 3-, and/or 6-position, optionally joined with the above-described linkers, according to bis-aminooxyalkanes of formula (5')

5



10 wherein  $t = 2-12$  and wherein one of the methylene groups can be replaced with O or S atoms or -NH- or -S-S- functions.

The cyclodextrin starting materials of the described reactions are well-known from literature.

15

Selection of a proper protecting group for aminooxy function is crucial, to be succesful in preparing the compounds of formula 1. In the present invention ethyl-N-hydroxyacetimidate fragment or alternatively acetonoxime  
20 were employed. Derivatives protected in such a way are stable in a large area of different reaction conditions and the derivatives can be readily converted to corresponding O-substituted hydroxylamines by acid treatment. In the case of ethoxylidene protection the masking group can be removed  
25 within 10-60 min at the room temperature with a diluted strong acid, exemplified by hydrohalides, sulfuric phosphoric, nitrous, and paratoluenesulfonic acids. On the contrary, removal of acetonoxime protection demands by refluxing with 20% (w/v) hydrochloric acid.

30

The invention is described in the following by nonlimiting examples.

## BRIEF DESCRIPTION OF DRAWINGS



- Figure 1a. Time course of the UV spectra (optical path length 1 mm) of a reaction mixture containing 1 mM 4-thiouracil in 100mM 4-aminooxy-2-butenyl-beta-cyclodextrin (I; see Example I.2) at pH 7.0. Incubation at 20°C is indicated as hours.
- Figure 1b. Time course of the UV spectra (optical path length 1 mm) of a reaction mixture containing 1 mM 4-thiouracil and 100 mM 1-aminooxybutane at 20°C at pH 7.00. Incubation time (hours) is indicated.
- Figure 2a. Time course of the UV spectra (optical path length 1 mm) of a reaction mixture containing 1 mM 6-mercaptapurineriboside with 100 mM 4-aminooxy-2-butenyl-beta-cyclodextrin (see Example I.2). Incubation time (hours) is indicated.
- Figure 2b. Time course of the UV spectra (optical path length 1 mm) of a reaction mixture containing 1 mM 6-mercaptapurineriboside with 100 mM 1-aminooxybutane at pH 7.00. Incubation time (hours) is indicated.

25

30

35

## Example I

I. 4-Aminooxy-2-butenyl- $\beta$ -cyclodextrin hydrochloride (I).

15 1. 3.1 g (14 mmols) of 1-ethoxyethylideneaminoxy-4-bromo-butene-2 (Khomutov A.R. and Khomutov R.M. (1986) *Bioorgan.Khim.*, Russ., v.12, No.12, p.1662-1674) was added to a solution of 2.26 g (2 mmols) of  $\beta$ -cyclodextrin in a mixture of 18.7 ml water and 1.3 ml of 10 N NaOH and heated

20 under nitrogen on a boiling water bath with intensive stirring until the pH turned neutral (usually 60-90 min). On cooling an oil separated. The product was washed with cold water and dissolved in 50 ml of i-PrOH and 4 ml of 5.0 N HCl was added. After a 30-minute incubation at 20°C, the

25 liquid was decanted and the residual oil crystallized with absolute i-PrOH. The precipitation was filtered and washed with absolute i-PrOH and dried over P<sub>2</sub>O<sub>5</sub>/KOH in vacuo, resulting in 2.80 g (90% yield) of (I). The amount of aminoxy groups was determined (Korpela T.K. and Makela


30 M.J. (1981) *Anal.Biochem.* v.110, No.2, p.251-258) and was 2.8 mmols/g, the low value indicating that only primary hydroxyl groups had reacted. NMR (Jeol-400, DMSO-d<sub>6</sub>) :

35 2. 7.7 g (35 mmols) of 1-ethoxyethylideneaminoxy-4--bromobutene-2 was added to a solution of 5.6 g (5 mmols) of  $\beta$ -cyclodextrin in a mixture of 70 ml of water and 3.4 ml

of 10 N NaOH and mixed with a magnetic stirrer at 20°C. After two days, 10 ml of i-PrOH was added and stirring continued at 20°C until the pH turned neutral (usually about 5-8 days). The solution was evaporated to dryness in vacuo, the residual oil washed with cold water and dissolved in 50 ml of i-PrOH and 10 ml of 5.0 N HCl was added. After a 30 minute incubation at 20°C, the liquid was decanted and the residual oil crystallized with absolute i-PrOH. The precipitation was filtered and washed with absolute i-PrOH and dried over P<sub>2</sub>O<sub>5</sub>/KOH in vacuo, resulting in 3.56 g (50% yield) of (I). The amount of aminoxy groups determined as above was 2.26 mmols/g. NMR data identical to that in ex.I.1.

#### Example II

##### 4-Aminoxy-2-butenyl- $\alpha$ -cyclodextrin hydrochloride (II).



2.8 g (12 mmols) of 1-ethoxyethylideneaminoxy-4-bromobutene-2 was added to a solution of 1.96 g (2 mmols) of  $\alpha$ -cyclodextrin (Sigma) in a mixture of 18.9 ml of water and 1.1 ml of 10 N NaOH and heated under nitrogen on a boiling water bath with intensive stirring until pH turned neutral (usually 60-90 min). The oil which separated on cooling was washed with cold water and dissolved in 50 ml i-PrOH. To this solution 4 ml of 5.0 N HCl was added. After 30 min incubation at 37°C, the liquid was decanted and the residual oil crystallized with i-PrOH. The precipitation was filtered, washed with absolute i-PrOH and dried over




15

P<sub>2</sub>O<sub>5</sub>/KOH in vacuo resulting in 2.21 g (69% yield) of II. The amount of aminoxy groups determined as above was 3,25 mmoles/g. NMR (Jeol-400, DMSO-d<sub>6</sub>) :

### 5 Example III

4-Aminoxy-2-butenyl-γ-cyclodextrin hydrochloride (III).




15

3.54 g (16 mmoles) of 1-ethoxyethylideneaminoxy-4-bromobutene-2 was added to a solution of 2.6 g (2 mmoles) of γ-cyclodextrin (Fluka) in a mixture of 18.5 ml of water and 1.5 ml of 10 N NaOH and heated under nitrogen on a boiling water bath with intensive stirring until the pH turned neutral (usually 60-90 min). The oil which separated on cooling was washed with cold water and dissolved in 50 ml of i-PrOH and 4 ml of 5.0 N HCl was added. After a 30-minute incubation at 20°C, the liquid was decanted and the residual oil crystallized with i-PrOH. The precipitation was filtered and washed with abs. i-PrOH and dried over P<sub>2</sub>O<sub>5</sub>/KOH in vacuo, resulting in 3.76 g (95% yield) of III. The amount of aminoxy groups determined as above was 2,86 mmoles/g. NMR (Jeol-400, DMSO- d<sub>6</sub>):

30


35

Example IV4-Aminoxybutyl- $\beta$ -cyclodextrin hydrochloride (IV).

3.1 g (14 mmoles) of 1-ethoxyethylideneaminoxybutylbromide (*Nedospasov A.A. and Khomutov R.M. (1976) Izv. AN SSSR Ser. Khim. (in Russian) No.9, p.2113-2115*) was added to a solution of 2.26 g (2 mmoles) of  $\beta$ -cyclodextrin in a mixture of 18.7 ml water, 0.21 g (1.4 mmoles) of NaI and 1.3 ml of 10 N NaOH and heated under nitrogen on a boiling water bath with intensive stirring until the pH turned neutral (12-18 hrs). The oil separated on chilling was washed with cold water and dissolved in 50 ml of i-PrOH. To this solution 4 ml of 5.0 N HCl was added, after 30 min incubation at 20°C the liquid was decanted and the residual oil crystallized upon abs. i-PrOH treatment. The precipitation was filtered and washed with abs. i-PrOH and dried over  $\text{P}_2\text{O}_5/\text{KOH}$  in vacuum, that gave 1.66 g (58% yield) of IV. The amount of aminoxy groups determined as above was 2.20 mmoles/g. NMR (Jeol-400,  $\text{DMSO}-d_6$ ) : 10.99 (m,  $\text{H}_2\text{N}-\text{O}-$ ), 4.84 (m,  $\text{C}_1-\text{H}$ ), 4.02 (m,  $\text{H}_2\text{NO}-\text{CH}_2-$ ), 3.76-3.38 (mm,  $\text{C}_3-\text{H}$ ,  $\text{C}_6-\text{H}$ ,  $\text{C}_5-\text{H}$ ,  $\text{C}_2-\text{H}$ ,  $\text{C}_4-\text{H}$ ), 1.62 (m,  $-\text{CH}_2-\text{CH}_2-$ ). NMR (Jeol-400,  $\text{D}_2\text{O}$ ) : 4.92 (m,  $\text{C}_1-\text{H}$ ), 3.95 (m,  $\text{H}_2\text{NO}-\text{CH}_2-$ ), 3.71-3.45 (mm,  $\text{C}_3-\text{H}$ ,  $\text{C}_6-\text{H}$ ,  $\text{C}_5-\text{H}$ ,  $\text{C}_2-\text{H}$ ,  $\text{C}_4-\text{H}$ ), 1.59 (m,  $-\text{CH}_2-\text{CH}_2-$ ).

Example VAcetonoxime of 4-Aminooxybutyl- $\beta$ -cyclodextrin (V).

5




10 To a solution of 1.5 g of (IV) in 15 ml of H<sub>2</sub>O-aceton mixture (1:1, V/V), diluted aqueous ammonia was added to a pH of 5-6. Then the reaction mixture was incubated for 2 h at 20°C. After evaporation to dryness, the residue was treated with water, the semi-solid product was separated and crystallized twice from water. The precipitate was filtered off, dried in vacuo over P<sub>2</sub>O<sub>5</sub>/KOH and 1.1 g (7 % yield) of (V) was obtained. NMR (Jeol-400, DMSO-d<sub>6</sub>) : 4.83 (m, C<sub>1</sub>-H), 3.92 (m, =NO-CH<sub>2</sub>-), 3.75-3.22 (m, C<sub>3</sub>-H, C<sub>6</sub>-H, C<sub>5</sub>-H, C<sub>2</sub>-H, C<sub>4</sub>-H), 1.77 (m, (CH<sub>3</sub>)<sub>2</sub>C=), 1.59 (m, -CH<sub>2</sub>-CH<sub>2</sub>-).


20

Example VIPyridoxal-5'-phosphate oxime of 4-aminooxybutyl- $\beta$ -cyclodextrin (VI).

25



30




35

To a solution of 10.6 mg pyridoxal-5'-phosphate ("Merck") in 1.24 ml 0.1 N NaOD in D<sub>2</sub>O, 20 mg of (IV) was added and

the reaction mixture was incubated for 2 hr. at 20°C. The compound (VI) was obtained with a yield being close to quantative. NMR (Jeol-400, D<sub>2</sub>O) : 8.39 (m, H-C=N-O-), 7.70 (m, α-H), 4.85 (m, C<sub>1</sub>-H), 4.74 (m, -CH<sub>2</sub>-O-P-), 4.33 (m, H<sub>2</sub>NO-CH<sub>2</sub>-), 3.72-3.32 (m, C<sub>3</sub>-H, C<sub>6</sub>-H, C<sub>5</sub>-H, C<sub>2</sub>-H, C<sub>4</sub>-H), 2.58 (m, α-CH<sub>3</sub>), 1.58 (m, -CH<sub>2</sub>-CH<sub>2</sub>-).

### Example VII


10 Mono-6-(2-ethoxyethylideneaminoxyethyl)thio-6-deoxy-β-cyclodextrin (VII).



To a solution of 0.74 g (4.5 mmoles) of 2-ethoxyethylideneamino-oxyethylmercaptane (Khomutov A.R. and Khomutov R.M. (1986) *Bioorg. Khim. (Russ.)* v.12, No.12, p.1662-1674) in 2.0 ml abs. MeOH was added 2.22 ml of 2 M MeONa/MeOH, after evaporation in vacuum to dryness the residue was dissolved in a mixture of 9.5 ml abs. DMSO and 0.5 ml MeOH and added to a solution of 1.95 g (1.5 mmoles) of mono-6-O-tosyl-β-cyclodextrin (Matsui Y. and Okimoto A. (1978) *Bull.Chem.Soc. (Japan)* v.51, No.10, p.3030-3034) in 15 ml abs. DMSO. The reaction was kept for 8 hr at 20°C, then 1.2 ml of 2 M AcOH in DMSO was added and the solution evaporated to dryness in vacuum. The residual oil solidified after water treatment, the precipitate was filtered off, washed with cold water, recrystallized twice from water and dried in vacuum over P<sub>2</sub>O<sub>5</sub>/KOH to give 1.3 g (yield 67 %) of VII. NMR (Jeol-400, DMSO-d<sub>6</sub>) : 4.86 (m, C<sub>1</sub>-H), 3.97 (q, CH<sub>3</sub>-CH<sub>2</sub>-O-), 3.94 (t, =NO-CH<sub>2</sub>-), 3.79-3.33 (mm, C<sub>3</sub>-H, C<sub>6</sub>-H, C<sub>5</sub>-H, C<sub>2</sub>-H, C<sub>4</sub>-H), 2.79 (m, -CH<sub>2</sub>-CH<sub>2</sub>-S-) 1.87 (s, CH<sub>3</sub>-), 1.23 (t, CH<sub>3</sub>-CH<sub>2</sub>-O-).

Example VIIIMono-6-(2-aminooxyethyl)thio-6-deoxy- $\beta$ -cyclodextrin hydrochloride (VIII)

5




10

1.25 g (1.0 mmoles) of (VII) were suspended in 20 ml of 1 N HCl, heating to 50°C gave clear solution, which was evaporated to dryness in vacuum. The residual oil solidified upon treatment with abs. i-PrOH. The precipitate was  
 15 filtered off, washed with abs. i-PrOH and dried over P<sub>2</sub>O<sub>5</sub>/KOH in vacuum that gave 0.80 g (65% yield) of (VIII). The amount of aminoxy groups determined as above was 0.88 mmoles/g. NMR (Jeol-400, DMSO-d<sub>6</sub>) : 4.85 (m, C<sub>1</sub>-H), 4.12 (t, H<sub>2</sub>NO-CH<sub>2</sub>-), 3.82-3.33 (mm, C<sub>3</sub>-H, C<sub>6</sub>-HC<sub>5</sub>-H-  
 20 C<sub>2</sub>-H, C<sub>4</sub>-H), 2.86 (m, CH<sub>2</sub>-CH<sub>2</sub>-S)

Example IX

25


Acetonoxime of mono-6-(2-aminoxyethyl)thio-6-deoxy- $\beta$ -cyclodextrin (IX).

To a solution of 0.62 g (0.5 mmoles) of (VIII) in 8.0 ml of a H<sub>2</sub>O-acetone cocktail (1:1, V/V), a diluted water NH<sub>3</sub>  
 35 solution was added to pH 5-6 and the reaction mixture was incubated for 2 h at 20°C. After evaporation to dryness,

the residue was crystallized twice from water. The precipitate was filtered off, dried in vacuum over  $P_2O_5/KOH$  and 0.5 g (80 % yield) of IX as obtained. NMR (Jeol-400, DMSO- $d_6$ ) : 4.85 (m,  $C_1-H$ ), 4.04 (t,  $=NO-CH_2-$ ), 3.79-3.36 (mm,  $C_3-H$ ,  $C_6-H$ ,  $C_5-H$ ,  $C_2-H$ ,  $C_4-H$ ), 2.77 (m,  $CH_2-CH_2-S$ ), 1.80 (d,  $CH_3-$ ).

#### Example X

#### 10 Mono-6-(4-ethoxyethylideneaminoxybutyl)thio-6-deoxy- $\beta$ -cyclodextrin (X)




15

Mono-6-(4-ethoxyethylideneaminoxybutyl)thio-6-deoxy- $\beta$ -cyclodextrin was obtained as is described for (VII) starting from 1.95 g (1.5 mmoles) of mono-6-O-tosyl- $\beta$ -cyclodextrin and 0.85 g (4.5 mmoles) of 4-ethoxyethylideneaminoxyethylmercaptan (Nedospasov A.A. and Khomutov R.M. (1976) *Izv. AN SSSR Ser. Khim. (in Russian)* No.9, p.2113-2115) that gave 1.56 g (80 % yield) of (X). NMR (Jeol-400, DMSO- $d_6$ ) : 4.84 (m,  $C_1-H$ ), 3.95 (q,  $CH_3-CH_2-O-$ ), 3.80 (t,  $=NO-CH_2-$ ), 3.75-3.31 (mm,  $C_3-H$ ,  $C_6-H$ ,  $C_5-H$ ,  $C_2-H$ ,  $C_4-H$ ), 2.68 (m,  $CH_2-CH_2-S$ ) 1.87 (d,  $CH_3-$ ), 1.56 (m,  $-CH_2-CH_2-$ ), 1.23 (t,  $CH_3-CH_2-O-$ ).

25

#### Example XI

#### 30 Mono-6-(4-aminoxybutyl)thio-6-deoxy- $\beta$ -cyclodextrin hydrochloride (XI)




35

Mono-6-(4-aminooxybutyl)thio-6-deoxy- $\beta$ -cyclodextrin hydrochloride was obtained as is described for (VIII), starting from 1.3 g (1.0 mmoles) of (X) that gave 1.0 g (75 % yield) of (XI). NMR (Jeol-400, DMSO- $d_6$ ) : 10.85 (m,  $H_2NO-$ ), 4.83 (m,  $C_1-H$ ), 3.99 (m,  $H_2NO-CH_2-$ ), 3.63-3.31 (mm,  $C_3-H$ ,  $C_6-H$ ,  $C_5-H$ ,  $C_2-H$ ,  $C_4-H$ ), 1.59 (m,  $-CH_2-CH_2-$ ).

### Example XII

10 Acetonoxime of mono-6-(2-aminooxyethyl)thio-6-deoxy- $\beta$ -cyclodextrin (XII).




The acetonoxime of mono-6-(2-aminooxyethyl)thio-6-deoxy- $\beta$ -cyclo-dextrin was obtained as is described for (IX) starting from 0.7 g of (XI) that gave 0.55 g (78 % yield) of (XII). NMR (Jeol-400, DMSO- $d_6$ ) : 4.82 (m,  $C_1-H$ ), 3.89 (t,  $=NO-CH_2-$ ), 3.61-3.32 (mm,  $C_3-H$ ,  $C_6-H$ ,  $C_5-H$ ,  $C_2-H$ ,  $C_4-H$ ), 2.92 (m,  $CH_2-CH_2-S$ ), 1.78 (d,  $CH_3-$ ), 1.52 (m,  $-CH_2-CH_2-$ ).

### Example XIII

25

Reaction of I with 4-thiouracil




35 A 1 mM solution of 4-thiouracil (Lachema, Brno, Czechoslovakia) was incubated at 20°C within a 0.1 M solution of 4-aminooxy-2-butenyl- $\beta$ -CD (I) at neutral pH. The UV-spectra were recorded at certain time intervals using

cuvettes of 1 mm optical path length (Figure 1a). This reaction was compared with the reaction of 4-thiouracil with 1-aminooxybutane under the same reaction conditions (Fig.1b). The results show significantly higher velocity of reaction with the aminooxy-2-butenyl- $\beta$ -CD.

#### Example XIV

Reaction of I with 6-mercaptopurine riboside



A 1 mM solution of 6-mercaptopurine riboside (Sigma Chem.Co., USA) was incubated at 20°C within 0.1 M of 4-aminooxy-2-butenyl- $\beta$ -CD (I). At certain time intervals UV-spectra were recorded in cuvettes of 1 mm optical path (Fig. 2a). The similar reaction with 1-aminooxybutane (Fig. 2b) showed drastically higher reaction rates with the CD-derivative.



1. Aminoxy-cyclodextrin derivatives of the formula 1:

$$5 \quad \text{CD} - (\text{X} - \text{Y} - \text{ONH}_2)_n, \quad (1)$$

CD is a mono- or polydeoxy  $\alpha$ -,  $\beta$ - or  $\gamma$ -cyclodextrin, carrying in its 6-, 3- and/or 2-position the aminooxy function containing group (X-Y-ONH<sub>2</sub>), and optionally carrying further substituents different from (X-Y-ONH<sub>2</sub>) in their 6-, 3- and/or 2-positions, and wherein Y is a linker group between the aminooxy group and the mono- or polydeoxy-CD-group,

15 X is a functional group or an atom necessary to connect the linker Y and the deoxy CD group, or Y is a direct bond when X is a direct bond,  
and n is  $\geq 1$ , but  $\leq 24$ , 21 and 18 for  $\alpha$ -,  $\beta$ - or  $\gamma$ -cyclo-  
dextrin, respectively, as well as the aminoxy protected  
20 derivatives thereof, especially ethoxy-ethylidene protected aminoxy and acetone oxime derivatives thereof.

2. A derivative according to claim 1, wherein Y and X are both direct bonds.

25 3. A derivative according to claim 1 or 2, wherein one or more of the primary hydroxy groups at a 6-position of  $\alpha$ -,  $\beta$ - or  $\gamma$ -CD are substituted with a X-Y-ONH<sub>2</sub> fragment, wherein X and Y have the meaning of claim 1.

30 4. A derivative according to any one of claims 1 and 3,  
wherein Y is a linear or branched alkylene, alkenylene with  
one or more double bounds which may be either isolated or  
conjugated, alkynylene with one or more triple bonds which  
35 may be either isolated or conjugated, or arylene or  
arylalkylene fragments where aryl may be substituted or not  
substituted, whereby the alkylene, alkenylene and alkynylene-

ne fragments may be linear or branched and preferably contain 2-12 C-atoms in the chain, and one or more of the chain members (methylene groups) may be replaced by -NH-, -O-, -S-, -S-S-, -C(O)NH-, -C(O)O-, -OP(O)(OH)O-, -S(O)-, SO<sub>2</sub>-, -CHR-, where R is preferably alkyl, aryl, -OR', -NH<sub>2</sub>, -NHR', -NR'<sub>2</sub>, -OH, -COOH, or -ONH<sub>2</sub> groups and where R' is alkyl, aryl, or acyl.

5. A derivative according to any one of the claims 1, 3 and 4, wherein X is -O-, -S-, -NH-, -NR"-, -OCO-, -NH-O-, =NO-, -NHC(O)-, -OP(O)(OH), -R"C=NO-, where R" is linear or branched lower alkyl.

6. A derivative according to the claims 4 or 5, wherein Y is alkylene containing 2-12 C-atoms, wherein one or more of the chain members may be replaced by -NH-, -O-, -S-, -C(O)NH-, -C(O)O-, or CHR<sub>1</sub> wherein R<sub>1</sub> is methyl, ethyl or propyl and X is -O-, -S-, -NH-, -OC(O)-, and -NH-C(O)-.


20

7. Any compound according to claim 1-6, wherein one or more of the hydroxyl groups at 6-, 3-, and/or 2- position(s) are substituted with a group, for example, H<sub>2</sub>N-, HS-, -COOH, alkoxy-, such as C<sub>1</sub> - C<sub>6</sub>- alkoxy-, aryloxy-, wherein aryl is preferably phenyl, benzyl, or tolyl, or with acyloxy group, wherein acyl preferably originates from C<sub>1</sub> - C<sub>6</sub>- carboxyl, or benzoic acids, and wherein alkyl-, aryl-, and acyloxy- can additionally contain functional groups like H<sub>2</sub>N-, HS-, -COOH in their structure, in side chain or in aromatic ring.


8. Method according to claim 1 or 3 for preparing compound of formula 1, wherein X is O, and wherein:

a) cyclodextrin of formula (3)

25




including  $R_2$ ,  $R_3$ , and  $R_4$  are hydroxyl groups or substituents  
 10 defined in claim 7, exemplified by unsubstituted alkoxy,  
 like  $C_1 - C_6$ - alkoxy or aryloxy like phenyl-, benzyl-,  
 tolyl-, or acyloxy, in which substituents' functional  
 groups, if they exist, are protected whenever necessary,  
 whereby at least one of the positions 6, 3, and/or 2 contain  
 15 hydroxyl group, preferably 6- hydroxy group, is alkylated  
 with a compound according to formula (3'):




wherein W means group  $-OC_2H_5$  or  $-CH_3$ , m and Y are as defined  
 in claims 1 or 3, and Z is a reactive group, preferably Cl,  
 Br, I, tosyl, mesyl or epoxy group, and optionally  
 25 protecting group(s) is/are removed, or

b) a cyclodextrin derivative of formula (4) is alkylated



wherein  $R'_2$ ,  $R'_3$ ,  $R'_4$  are hydroxy or activated groups like tosyl, mesyl, halogen, ester, epoxy, preferably tosyl or halogen, possibly bound through a linker group, like alkylen, or substituent as defined in claim 7, said substituent being in a protected form if necessary, whereby the CD-derivative contains at least one of said activated groups with the compound of formula (4')




10

wherein X and Y are as in claim 1, or as in 3 and 4, and X is preferably S or HN- fragment and Y has the meaning defined in claim 6, and W is defined as above, and protecting group(s) is/are possibly removed if necessary, or

15

c) a cyclodextrin derivative of compound with formula (5)

20



25

wherein at least one of the groups  $R''_2$ ,  $R''_3$ , and  $R''_4$  mean thiol-, amino-, karboxy- etc. group possibly linked directly to deoxy-CD-ring, or mean alkyleneoxy- or acyloxy groups, which contain at least one thiol-, amino-, karboxy-, etc. group, or their derivative, and the remaining functional groups are hydroxyl groups or they have the meaning described in claim 7 for the substituents, and exist, if necessary, in a protected form, typical example being unsubstituted alkoxy, aryloxy, or acyloxy, modified with an appropriate aminoxy protected substituted hydroxylamine according to formula (3'), after which the protecting

30

35

5 group(s) are removed, or

d) CD-derivative of formula (5), which contains one or more of keto or aldehyde groups, possibly bound through a linker group, is allowed to react with bisaminooxy alkanes of formula (5')

10



wherein t is 2-12, and wherein one of the methylene groups  
15 can be substituted with oxygen or sulfur atom, or wherein -NH- or -S-S- groups, and a protecting group is removed if necessary.

20 9. The use of any of the CD-derivatives of claims 1-7 for preparation of oximes with ketones or aldehydes, for preparation of aminooxy derivatives of nucleotide- and nucleoside pyrimidines or purines, or for preparation of inclusion complexes with guest molecules by said CD-  
25 derivatives.

10. Oximes of any one of the aminooxy-CDs of claim 1-7 with a synthetic or natural aldehydes or ketones.

30 11. Derivatives of nucleotide or nucleoside pyrimidines or purines with aminooxy-CDs, wherein aminooxy group is linked to heterocyclic ring, preferably through pyrimidine C-4 and purine C-6, and wherein pyrimidine and purine are preferably cytosine or adenine as such or as their derivatives.

35




Figure 1 a

SUBSTITUTE SHEET (RULE 26)

2/4




Figure 1 b

SUBSTITUTE SHEET (RULE 26)

3/4




Figure 2 a

SUBSTITUTE SHEET (RULE 26)



4/4




Figure 2 b

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 99/00167

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C08B 37/16, A61K 47/40

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C08B, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, REGISTRY, CAPLUS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9641813 A2 (OFFORD, ROBIN), 27 December 1996 (27.12.96), page 10, 3rd paragraph - page 11, 1st paragraph; page 13, 1st paragraph; page 20, 2nd paragraph --	1-11
X	STN International, File CAPLUS, CAPLUS accession no. 1976:526050, document no. 85:126050, Nedospasov, A. A. et al: "Synthesis and some properties of aminoxyalkyl celluloses"; & Izv. Akad. Nauk SSSR, Ser. Khim. (1976), (5), 1136-41 --	1-9

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 June 1999

Date of mailing of the international search report

23-06-1999

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Helena Danielsson/EÖ  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 99/00167

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Bioorganic Chemistry, Volume 14, 1986, D. V. P. R. Varaprasad et al, "Synthesis of Polyfunctional Hydroxamic Acids for Potential Use in Iron Chelation Therapy" page 8 - page 16 --	1-9
Y	STN International, File CAPLUS, CAPLUS accession no.1978:510174, document no. 89:110174, Nedospasov, A. A. et al: "Synthesis of aminooxydextrans and adsorbents based on them"; & Izv, Akad. Nauk SSSR, Ser. Khim. (1978), (4), 962-4 --	1-9
A	File WPI, Derwent accession no. 88-153418, AS USSR MOLECULAR et al: "Prepn. of amino hydroxy-butenyl cellulose - by alkenylating cellulose with excess of ethoxy-ethylidene-amino-hydroxy bromobutene in diluted aq. sodium hydroxide"; & SU,A,1348345, 871030 --	1-7
A	Bioorganic & Medicinal Chemistry Letters, Volume 4, No 16, 1994, Mark A. Mortellaro et al, "Synthesis of beta-Cyclodextrin Oximes" page 2041 - page 2044 --	1-10
P,X	STN International, File CAPLUS, CAPLUS accession no. 1998:600670, document no. 129:302779, Hori, Yuji et al: "Effects of solvents on the chirality of ferrichrome-mimicking Fe <sup>3+</sup> complexes based on .alpha.-cyclodextrin"; & Nippon Kagaku Kaishi (1998 September), 602-608 -- -----	1-11

## 01/06/99

PCT/FI 99/00167

Form PCT/ISA/210 (patent family annex) (July 1992)